N-(2-chloromethyl-benzyl)-phthalimide | 117682-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-(2-chloromethyl-benzyl)-phthalimide
• 英文别名: N-(2-Chlormethyl-benzyl)-phthalimid；2-[2-(chloromethyl)benzyl]-1H-isoindole-1,3(2H)-dione；N-(2-chloromethylbenzyl)phthalimide；2-[[2-(chloromethyl)phenyl]methyl]isoindole-1,3-dione
• CAS: 117682-19-6
• 化学式: C₁₆H₁₂ClNO₂
• 分子量: 285.73
• InChiKey: LLKMKOGCKGVFNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-chloromethyl-benzyl)-phthalimide 在 甲醇 、 肼 作用下， 以77%的产率得到4-{[2-(aminomethyl)benzyl]oxy}-3-chloro-1-(4-chloro-3-methoxybenzyl)-6-methylpyridin-2(1H)-one
  参考文献：
  名称：

  WO2007/91176

  摘要：

  公开号：
• 作为产物：
  描述：

  potassium phtalimide 、 alkaline earth salt of/the/ methylsulfuric acid 生成 N-(2-chloromethyl-benzyl)-phthalimide
  参考文献：
  名称：

  Strassmann, Chemische Berichte, 1888, vol. 21, p. 580

  摘要：

  DOI：

文献信息

• S-adenosyl methionine decarboxylase inhibitors
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05416076A1

  公开（公告）日：1995-05-16

  The adenosine derivatives represented by the following formula: ##STR1## and the pharmaceutically acceptable salts thereof wherein R is H or C.sub.1 -C.sub.7 alkyl, Q is the moiety of the formula ##STR2## wherein V is H or --COOH X is H, F, Cl, Br, and Z is H, F, Cl, or Br. These compounds are inhibitors of S-adenosylmethione decarboxylase and are useful for treating parasitic infections.

  以下公式所代表的腺苷衍生物：##STR1##以及其药学上可接受的盐，其中R为H或C.sub.1-C.sub.7烷基，Q为公式##STR2##中的基团，其中V为H或--COOH，X为H、F、Cl、Br，Z为H、F、Cl或Br。这些化合物是S-腺苷甲硫氨酸脱羧酶的抑制剂，可用于治疗寄生虫感染。
• 5'-amine substituted adenosine analogs as immunosuppressants
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05308837A1

  公开（公告）日：1994-05-03

  The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-amine substituted adenosine analogs.

  本发明涉及一种用于对需要免疫抑制的患者进行免疫抑制的方法，包括向该患者施用一定量有效的免疫抑制剂，该免疫抑制剂为某些5'-氨基取代腺苷类似物。
• Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
  申请人：Devadas Balekudru

  公开号：US20090270350A1

  公开（公告）日：2009-10-29

  This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygeπase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R 1 , R 2a , R 2b , R 2c , R 2d , R 2e , R 3a , R 3b , R 3c , R 3d , R 4 , R 5 , R 6 , R 7a , R 7b , R 7c , R 7d and R 7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

  本发明通常涉及取代的吡啶酮和嘧啶酮化合物，它们通常抑制p38激酶、TNF和/或环氧合酶活性。这些取代的吡啶酮和嘧啶酮化合物包括通常对应于以下结构公式的化合物：其中Z、n、R1、R2a、R2b、R2c、R2d、R2e、R3a、R3b、R3c、R3d、R4、R5、R6、R7a、R7b、R7c、R7d和R7e如本说明书所定义。本发明还涉及这些取代的吡啶酮和嘧啶酮（特别是药物组成物）的组成物，以及用于治疗与p38激酶活性、TNF活性和/或环氧合酶-2活性相关的疾病（通常是病理性疾病）的方法。
• The impact of spacer structure on 5-HT7 and 5-HT1A receptor affinity in the group of long-chain arylpiperazine ligands
  作者：Andrzej J. Bojarski、Beata Duszyńska、Marcin Kołaczkowski、Piotr Kowalski、Teresa Kowalska

  DOI：10.1016/j.bmcl.2004.09.029

  日期：2004.12

  New cis-, trans-2-butene and 1,2-bismethylbenzene analogues of MM77 and NAN-190 (1-4-[4-(2-methoxyphenyl)-piperazin-1-yl]-butyl}-pyrrolidine-2,5-dione and isoindole-1,3-dione, respectively) were synthesized. The differences in their in vitro affinity for serotonin 5-HT7 and 5-HT1A receptors were explained using a conformational analysis. A bioactive conformation of those compounds for the 5-HT7 receptor, different from that established for 5-HT1A, was proposed. (C) 2004 Elsevier Ltd. All rights reserved.
• PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES
  申请人：Pfizer Products Inc.

  公开号：EP1987022A1

  公开（公告）日：2008-11-05